Skip to main content

These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) and insights into APDS and additional primary immunodeficiencies (PIDs) with immune dysregulation.

Read the full press release below for more details on the presentations.

Cookies: This website uses cookies Check the cookies page for more information Accept Decline